Shohei Yoshiya
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Shohei Yoshiya has a total of 229 co-authors. Here are the top co-authors by number of shared publications:
Tomoharu Yoshizumi
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
42 shared publicationsYoshihiko Maehara
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
37 shared publicationsToru Ikegami
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
28 shared publications- Shinji Itoh
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, 812-8582, Japan
22 shared publications Takeo Toshima
Department of Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan
20 shared publications- Tomoharu Yoshizumi
Department of Surgery and Science Graduate School of Medical Sciences Kyushu University Fukuoka Japan
19 shared publications
Latest Publications
- 12 October 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Prognostic Impact of the C‐Reactive Protein–Albumin–Lymphocyte ( CALLY ) Index in Patients With Hepatocellular Carcinoma Undergoing Living Donor Liver Transplantation
Background: The C‐reactive protein–albumin–lymphocyte (CALLY) index reflects systemic inflammation, nutritional status, and immune competence. However, its prognostic significance in patients undergoing living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) remains unclear. Methods: We retrospectively analyzed 239 patients with HCC who underwent LDLT. Prognostic performance, clinicopathological associations, and post‐transplant outcomes were evaluated using Cox regression, competing‐risk analysis, and internal validation. Results: The 5‐year area under the curve for the CALLY index was 0.65 (95% confidence interval [CI], 0.53–0.77). Low CALLY was associated with worse overall survival ( p = 0.0134) and higher 1‐year mortality (12.7% vs. 4.0%, p = 0.0153). In multivariable analysis, low CALLY was associated with higher mortality (hazard ratio, 2.17; 95% CI, 1.20–3.93; p = 0.0099). Adding CALLY to the clinical model increased the apparent C‐index from 0.513 to 0.612 (ΔC‐index, 0.099; p = 0.042), although calibration was similar. CALLY was not associated with HCC recurrence, whereas elevated PIVKA‐II was. Conclusion: Low CALLY was associated with higher mortality after LDLT for HCC and appears to reflect recipient condition rather than recurrence risk. It may be useful for preoperative risk assessment.
- 12 October 2026
- Published by Wiley in Journal of Hepato-Biliary-Pancreatic Sciences
Prognostic Impact of the C‐Reactive Protein–Albumin–Lymphocyte ( CALLY ) Index in Patients With Hepatocellular Carcinoma Undergoing Living Donor Liver Transplantation
Background: The C‐reactive protein–albumin–lymphocyte (CALLY) index reflects systemic inflammation, nutritional status, and immune competence. However, its prognostic significance in patients undergoing living donor liver transplantation (LDLT) for hepatocellular carcinoma (HCC) remains unclear. Methods: We retrospectively analyzed 239 patients with HCC who underwent LDLT. Prognostic performance, clinicopathological associations, and post‐transplant outcomes were evaluated using Cox regression, competing‐risk analysis, and internal validation. Results: The 5‐year area under the curve for the CALLY index was 0.65 (95% confidence interval [CI], 0.53–0.77). Low CALLY was associated with worse overall survival ( p = 0.0134) and higher 1‐year mortality (12.7% vs. 4.0%, p = 0.0153). In multivariable analysis, low CALLY was associated with higher mortality (hazard ratio, 2.17; 95% CI, 1.20–3.93; p = 0.0099). Adding CALLY to the clinical model increased the apparent C‐index from 0.513 to 0.612 (ΔC‐index, 0.099; p = 0.042), although calibration was similar. CALLY was not associated with HCC recurrence, whereas elevated PIVKA‐II was. Conclusion: Low CALLY was associated with higher mortality after LDLT for HCC and appears to reflect recipient condition rather than recurrence risk. It may be useful for preoperative risk assessment.
- 28 August 2026
- Published by Wiley in Hepatology Research
Nuclear Pan‐Lysine Lactylation Immunoreactivity Is Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma
Aim: Lysine lactylation (Kla) links cellular metabolism to gene regulation, but its significance in intrahepatic cholangiocarcinoma (ICC) remains unclear. Methods: Nuclear pan‐Kla immunoreactivity was evaluated in 118 patients who underwent curative‐intent resection for ICC. Associations with clinicopathological features, overall survival (OS), recurrence‐free survival (RFS), and FDG‐PET‐derived SUVmax were analyzed. Functional assays and bulk RNA sequencing were performed in cholangiocarcinoma cells treated with lactate, the p300 inhibitor A‐485, or the LDH inhibitor oxamate. Results: High nuclear pan‐Kla immunoreactivity was associated with microscopic intrahepatic metastasis and poorer OS and RFS, and remained independently associated with both outcomes after multivariable adjustment. Adding Kla modestly increased the optimism‐corrected C‐index for OS, whereas RFS discrimination was not improved. Lactate increased pan‐Kla signals but produced minimal phenotypic and transcriptional changes. In contrast, p300 or LDH inhibition reduced pan‐Kla signals and was accompanied by reduced cell viability, colony formation, and wound closure; however, these effects cannot be attributed specifically to reduced Kla because A‐485 and oxamate are not Kla‐specific. RNA sequencing showed suppression of E2F target and G2M checkpoint programs. In an exploratory PET subgroup, the Kla H‐score correlated weakly with SUVmax, and patients with high Kla and high SUVmax had the poorest outcomes. Conclusions: Nuclear pan‐Kla immunoreactivity was independently associated with poor postoperative outcomes in resected ICC. Pharmacological modulation of lactylation‐related pathways was accompanied by suppression of proliferative and cell cycle‐related programs, although Kla‐specific causality remains to be established.
- 28 August 2026
- Published by Wiley in Hepatology Research
Nuclear Pan‐Lysine Lactylation Immunoreactivity Is Associated With Poor Prognosis in Intrahepatic Cholangiocarcinoma
Aim: Lysine lactylation (Kla) links cellular metabolism to gene regulation, but its significance in intrahepatic cholangiocarcinoma (ICC) remains unclear. Methods: Nuclear pan‐Kla immunoreactivity was evaluated in 118 patients who underwent curative‐intent resection for ICC. Associations with clinicopathological features, overall survival (OS), recurrence‐free survival (RFS), and FDG‐PET‐derived SUVmax were analyzed. Functional assays and bulk RNA sequencing were performed in cholangiocarcinoma cells treated with lactate, the p300 inhibitor A‐485, or the LDH inhibitor oxamate. Results: High nuclear pan‐Kla immunoreactivity was associated with microscopic intrahepatic metastasis and poorer OS and RFS, and remained independently associated with both outcomes after multivariable adjustment. Adding Kla modestly increased the optimism‐corrected C‐index for OS, whereas RFS discrimination was not improved. Lactate increased pan‐Kla signals but produced minimal phenotypic and transcriptional changes. In contrast, p300 or LDH inhibition reduced pan‐Kla signals and was accompanied by reduced cell viability, colony formation, and wound closure; however, these effects cannot be attributed specifically to reduced Kla because A‐485 and oxamate are not Kla‐specific. RNA sequencing showed suppression of E2F target and G2M checkpoint programs. In an exploratory PET subgroup, the Kla H‐score correlated weakly with SUVmax, and patients with high Kla and high SUVmax had the poorest outcomes. Conclusions: Nuclear pan‐Kla immunoreactivity was independently associated with poor postoperative outcomes in resected ICC. Pharmacological modulation of lactylation‐related pathways was accompanied by suppression of proliferative and cell cycle‐related programs, although Kla‐specific causality remains to be established.
- 15 August 2026
- Published by Wiley in Hepatology Research
Time Matters More Than Distance: The Impact of Transport Logistics on Total Ischemic Time and Survival After Deceased‐Donor Liver Transplantation
Background: Total ischemic time (TIT) is a key determinant of outcomes after deceased‐donor liver transplantation (DDLT). In Japan, the nationwide organ allocation system, which does not include regional prioritization, often requires long‐distance graft transport. However, the contributions of transport time, distance, and modality to TIT and post‐transplant outcomes have not been fully clarified. Methods: We performed a nationwide retrospective cohort study of DDLT cases in Japan between July 2019 and December 2023 using data from the Japan Organ Transplant Network. Associations among transport‐related factors, TIT, and post‐transplant outcomes were assessed. Results: Among the 415 transplant recipients, TIT was significantly correlated with both transport time and transport distance ( p < 0.01), although the strength of these correlations varied according to transport modality. Strong correlations were observed for ground and high‐speed rail transportation, whereas the correlation was weaker for air transportation. Restricted cubic spline analyses demonstrated strong, monotonic associations between prolonged TIT and increased mortality risk and between prolonged transport time and mortality risk. Prolonged TIT was independently associated with poorer survival in the multivariable analysis, whereas transport time and modality were not. In the analyses stratified by the combination of TIT and transport time, favorable outcomes were observed in cases with a prolonged transport time when TIT was maintained at a lower level. Conclusion: Prolonged transport time contributes to increased TIT; however, optimization of perioperative management to minimize TIT may preserve post‐transplantation outcomes in long‐distance transplantation.
- 15 August 2026
- Published by Wiley in Hepatology Research
Time Matters More Than Distance: The Impact of Transport Logistics on Total Ischemic Time and Survival After Deceased‐Donor Liver Transplantation
Background: Total ischemic time (TIT) is a key determinant of outcomes after deceased‐donor liver transplantation (DDLT). In Japan, the nationwide organ allocation system, which does not include regional prioritization, often requires long‐distance graft transport. However, the contributions of transport time, distance, and modality to TIT and post‐transplant outcomes have not been fully clarified. Methods: We performed a nationwide retrospective cohort study of DDLT cases in Japan between July 2019 and December 2023 using data from the Japan Organ Transplant Network. Associations among transport‐related factors, TIT, and post‐transplant outcomes were assessed. Results: Among the 415 transplant recipients, TIT was significantly correlated with both transport time and transport distance ( p < 0.01), although the strength of these correlations varied according to transport modality. Strong correlations were observed for ground and high‐speed rail transportation, whereas the correlation was weaker for air transportation. Restricted cubic spline analyses demonstrated strong, monotonic associations between prolonged TIT and increased mortality risk and between prolonged transport time and mortality risk. Prolonged TIT was independently associated with poorer survival in the multivariable analysis, whereas transport time and modality were not. In the analyses stratified by the combination of TIT and transport time, favorable outcomes were observed in cases with a prolonged transport time when TIT was maintained at a lower level. Conclusion: Prolonged transport time contributes to increased TIT; however, optimization of perioperative management to minimize TIT may preserve post‐transplantation outcomes in long‐distance transplantation.
- Open Access
- 7 August 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Spatiotemporal dynamics of the tumor microenvironment in hepatocellular carcinoma during combination immunotherapy
Background: Atezolizumab plus bevacizumab (ATZ/BEV) is a standard first-line therapy for advanced hepatocellular carcinoma (HCC); however, many patients do not achieve meaningful tumor regression. The temporal and spatial immune remodeling associated with ATZ/BEV remains poorly understood. Methods: We performed single-cell RNA sequencing of paired hepatectomy specimens obtained before and after ATZ/BEV from one patient and of tumor center and margin samples from another patient after ATZ/BEV. Cell composition, subclusters, and cell–cell communication were analyzed. In addition, candidate molecules identified by transcriptomic analysis were further assessed using serum-based assays and immunohistochemistry. Results: These single-cell analyses suggested that ATZ/BEV was associated with a shift toward an immune-active tumor microenvironment, with increased CD8 + T cells together with reduced endothelial cells. CD8 + T cells showed increased effector and exhaustion signatures, indicating coexistence of activation and dysfunction. CellChat analysis demonstrated selective activation of the TIGIT–PVR/NECTIN2 axis after treatment. Spatial analysis showed that the tumor margin was enriched for CD8 + T cells and exhibited stronger effector and exhaustion activity than the tumor center. Immunoregulatory signaling was also more prominent at the margin. Serum TIGIT levels were significantly higher after ATZ/BEV than in upfront resection cases ( p =0.0325). Immunohistochemistry showed greater margin-to-center differences in TIGIT ( p =0.0019) and PVR ( p =0.0008) in the tumor after ATZ/BEV. Conclusions: Our exploratory findings suggest that ATZ/BEV may remodel the HCC microenvironment toward a state characterized by concurrent CD8 + T-cell activation and inhibitory signaling through the TIGIT–PVR/NECTIN2 axis, particularly at the tumor margin.
- 7 August 2026
- Published by Wolters Kluwer Health in Hepatology Communications
- Vol. 10 (9)
Open AccessSpatiotemporal dynamics of the tumor microenvironment in hepatocellular carcinoma during combination immunotherapy
Background: Atezolizumab plus bevacizumab (ATZ/BEV) is a standard first-line therapy for advanced hepatocellular carcinoma (HCC); however, many patients do not achieve meaningful tumor regression. The temporal and spatial immune remodeling associated with ATZ/BEV remains poorly understood. Methods: We performed single-cell RNA sequencing of paired hepatectomy specimens obtained before and after ATZ/BEV from one patient and of tumor center and margin samples from another patient after ATZ/BEV. Cell composition, subclusters, and cell–cell communication were analyzed. In addition, candidate molecules identified by transcriptomic analysis were further assessed using serum-based assays and immunohistochemistry. Results: These single-cell analyses suggested that ATZ/BEV was associated with a shift toward an immune-active tumor microenvironment, with increased CD8 + T cells together with reduced endothelial cells. CD8 + T cells showed increased effector and exhaustion signatures, indicating coexistence of activation and dysfunction. CellChat analysis demonstrated selective activation of the TIGIT–PVR/NECTIN2 axis after treatment. Spatial analysis showed that the tumor margin was enriched for CD8 + T cells and exhibited stronger effector and exhaustion activity than the tumor center. Immunoregulatory signaling was also more prominent at the margin. Serum TIGIT levels were significantly higher after ATZ/BEV than in upfront resection cases ( p =0.0325). Immunohistochemistry showed greater margin-to-center differences in TIGIT ( p =0.0019) and PVR ( p =0.0008) in the tumor after ATZ/BEV. Conclusions: Our exploratory findings suggest that ATZ/BEV may remodel the HCC microenvironment toward a state characterized by concurrent CD8 + T-cell activation and inhibitory signaling through the TIGIT–PVR/NECTIN2 axis, particularly at the tumor margin.
- 30 March 2026
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 36 (4)
Optimal Surgical Approach for Peri-Portal Vein Pancreatic Body Cancer: From the Pancreatic Tail or Head Side?
Objective: For peri-portal vein (PV) pancreatic body (Pb) cancer, we have often encountered difficulties in selecting the appropriate surgical approach—whether from the pancreatic tail side or the head side. This study aimed to clarify which procedure is more suitable for peri-PV Pb cancer. Methods: We reviewed 30 cases of peri-PV Pb cancer. The resected status of lymph nodes, their positivity rates in each procedure, and postoperative recurrence patterns were analyzed. Results: Among the 30 patients, 26 underwent distal pancreatectomy (DP), 3 underwent pancreatoduodenectomy, and 1 underwent total pancreatectomy. In the DP group, the gastroduodenal artery (GDA) was dissected to secure resection margins in 4 cases. The pancreatic transection lines were as follows: 1 to the right of the GDA, 3 at the GDA, 8 to the left of the GDA, and 14 to the right of the PV. Pathologic findings revealed the highest rate of lymph node metastasis in the splenic lymph nodes (#11, 32.1%), followed by the common hepatic lymph nodes (#8, 30.0%) and subpancreatic lymph nodes (#18, 18.5%). Only 1 case involved metastasis outside the regional Pb nodes—posterior pancreatic head (#13)—in a patient with suspected preoperative GDA invasion. Postoperative recurrence analysis showed no critical lymph node recurrence in nodes not resected during the initial procedure. Conclusions: This study suggests that DP may be an optimal option for peri-PV pancreatic body cancer without invasion of the pancreatic head region.
- 30 March 2026
- Published by Wolters Kluwer Health in Surgical Laparoscopy, Endoscopy & Percutaneous Techniques
- Vol. 36 (4)
Optimal Surgical Approach for Peri-Portal Vein Pancreatic Body Cancer: From the Pancreatic Tail or Head Side?
Objective: For peri-portal vein (PV) pancreatic body (Pb) cancer, we have often encountered difficulties in selecting the appropriate surgical approach—whether from the pancreatic tail side or the head side. This study aimed to clarify which procedure is more suitable for peri-PV Pb cancer. Methods: We reviewed 30 cases of peri-PV Pb cancer. The resected status of lymph nodes, their positivity rates in each procedure, and postoperative recurrence patterns were analyzed. Results: Among the 30 patients, 26 underwent distal pancreatectomy (DP), 3 underwent pancreatoduodenectomy, and 1 underwent total pancreatectomy. In the DP group, the gastroduodenal artery (GDA) was dissected to secure resection margins in 4 cases. The pancreatic transection lines were as follows: 1 to the right of the GDA, 3 at the GDA, 8 to the left of the GDA, and 14 to the right of the PV. Pathologic findings revealed the highest rate of lymph node metastasis in the splenic lymph nodes (#11, 32.1%), followed by the common hepatic lymph nodes (#8, 30.0%) and subpancreatic lymph nodes (#18, 18.5%). Only 1 case involved metastasis outside the regional Pb nodes—posterior pancreatic head (#13)—in a patient with suspected preoperative GDA invasion. Postoperative recurrence analysis showed no critical lymph node recurrence in nodes not resected during the initial procedure. Conclusions: This study suggests that DP may be an optimal option for peri-PV pancreatic body cancer without invasion of the pancreatic head region.
- 9 March 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (6) , 966-975
Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
Background: Complications associated with the Fontan circulation have become evident in recent years. Fontan‐associated liver disease (FALD) has attracted particular attention. However, many aspects of this condition including FALD‐associated hepatocellular carcinoma (FALD‐HCC) remain unclear. Patients and Methods: Since 2018, 12 liver resections for FALD‐HCC were performed in 9 patients at our institution. These 12 procedures were reviewed, and 9 cases of primary HCC were compared with 216 cases of primary HCC resection performed during the same period in non‐FALD patients in terms of short‐ and long‐term outcomes. Results: Among 12, nine were initial and three were recurrences. Approaches included open ( n = 6), laparoscopic ( n = 4), and robotic surgery ( n = 2). Compared with non‐FALD patients, FALD group was younger (37 vs. 69 years, p < 0.0001), had lower BMI (19.0 vs. 24.1, p = 0.0002) and showed advanced fibrosis/cirrhosis (F3–4) more frequently ( p = 0.03). Intraoperative blood loss was greater in the FALD group (1695 vs. 520 mL, p = 0.0003). Factors associated with blood loss > 1000 mL included CVP > 12 mmHg, tumor size > 2 cm, tumor depth > 3 cm from the liver surface. Among nine patients under regular post‐Fontan imaging surveillance, tumors tended to be smaller and blood loss lower. With a mean follow‐up period of 32.1 months in the FALD group, recurrence‐free survival did not differ between the groups. Conclusion: Long‐term outcomes seem comparable between FALD and non‐FALD HCC. In particular, FALD‐HCC ≤ 2 cm and close to the liver surface with CVP ≤ 12 mmHg could be potential candidates for surgical resection, including minimally invasive approaches. Post‐Fontan surveillance may be crucial.
- 9 March 2026
- Published by Wiley in Hepatology Research
- Vol. 56 (6) , 966-975
Surgical Resections for Hepatocellular Carcinomas Arising From Fontan‐Associated Liver Disease; Open, Laparoscopic and Robotic Hepatectomies
Background: Complications associated with the Fontan circulation have become evident in recent years. Fontan‐associated liver disease (FALD) has attracted particular attention. However, many aspects of this condition including FALD‐associated hepatocellular carcinoma (FALD‐HCC) remain unclear. Patients and Methods: Since 2018, 12 liver resections for FALD‐HCC were performed in 9 patients at our institution. These 12 procedures were reviewed, and 9 cases of primary HCC were compared with 216 cases of primary HCC resection performed during the same period in non‐FALD patients in terms of short‐ and long‐term outcomes. Results: Among 12, nine were initial and three were recurrences. Approaches included open ( n = 6), laparoscopic ( n = 4), and robotic surgery ( n = 2). Compared with non‐FALD patients, FALD group was younger (37 vs. 69 years, p < 0.0001), had lower BMI (19.0 vs. 24.1, p = 0.0002) and showed advanced fibrosis/cirrhosis (F3–4) more frequently ( p = 0.03). Intraoperative blood loss was greater in the FALD group (1695 vs. 520 mL, p = 0.0003). Factors associated with blood loss > 1000 mL included CVP > 12 mmHg, tumor size > 2 cm, tumor depth > 3 cm from the liver surface. Among nine patients under regular post‐Fontan imaging surveillance, tumors tended to be smaller and blood loss lower. With a mean follow‐up period of 32.1 months in the FALD group, recurrence‐free survival did not differ between the groups. Conclusion: Long‐term outcomes seem comparable between FALD and non‐FALD HCC. In particular, FALD‐HCC ≤ 2 cm and close to the liver surface with CVP ≤ 12 mmHg could be potential candidates for surgical resection, including minimally invasive approaches. Post‐Fontan surveillance may be crucial.
- 9 February 2026
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1387-1394
Postoperative outcomes of pancreatoduodenectomy for pancreatic head malignancy in patients over 85 years of age: A safety evaluation using propensity score matching
Introduction As the global population ages, older patients undergo pancreatoduodenectomy (PD). This study aimed to evaluate the safety and postoperative outcomes of PD in patients > 85 years of age. Methods We reviewed 200 consecutive PDs and compared the postoperative outcomes in patients aged ≥ 85 years using propensity score matching (PSM). Results After PSM, no differences in the clinical characteristics were observed between the two cohorts (n = 16 each). Those aged ≥ 85 years had a significantly lower induction rate of adjuvant chemotherapy (p < 0.0001) and a higher rate of best supportive care selection at recurrence (BSC) (p = 0.033) than those aged < 85 years. There was no significant difference in the rate of non-cancer-related deaths (p = 0.18). Although there were no significant differences in the -free survival rates (p = 0.89), the overall survival rate of those ≥ 85 years was significantly worse (p = 0.023). The risk factors for death after surgery were tumor-related factors and BSC (p = 0.0012). An age ≥ 85 years was not a risk factor for major postoperative complications or death after surgery. Conclusions PD can be safely performed in patients aged ≥ 85 years without increasing postoperative complications and recurrences in the cases with appropriate patient selection.
- 9 February 2026
- Published by Springer Nature in Surgery Today
- Vol. 56 (7) , 1387-1394
Postoperative outcomes of pancreatoduodenectomy for pancreatic head malignancy in patients over 85 years of age: A safety evaluation using propensity score matching
Introduction As the global population ages, older patients undergo pancreatoduodenectomy (PD). This study aimed to evaluate the safety and postoperative outcomes of PD in patients > 85 years of age. Methods We reviewed 200 consecutive PDs and compared the postoperative outcomes in patients aged ≥ 85 years using propensity score matching (PSM). Results After PSM, no differences in the clinical characteristics were observed between the two cohorts (n = 16 each). Those aged ≥ 85 years had a significantly lower induction rate of adjuvant chemotherapy (p < 0.0001) and a higher rate of best supportive care selection at recurrence (BSC) (p = 0.033) than those aged < 85 years. There was no significant difference in the rate of non-cancer-related deaths (p = 0.18). Although there were no significant differences in the -free survival rates (p = 0.89), the overall survival rate of those ≥ 85 years was significantly worse (p = 0.023). The risk factors for death after surgery were tumor-related factors and BSC (p = 0.0012). An age ≥ 85 years was not a risk factor for major postoperative complications or death after surgery. Conclusions PD can be safely performed in patients aged ≥ 85 years without increasing postoperative complications and recurrences in the cases with appropriate patient selection.
- Open Access
- 28 January 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1165-1173
Risk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation
Background: Small‐for‐size syndrome (SFSS) after adult living‐donor liver transplantation (LDLT) is a poor prognostic condition. Splenectomy (Spx) has recently been reported to help prevent SFSS and improve outcomes. This study aimed to identify risk factors for SFSS that occur despite Spx at the time of LDLT. Methods: This single‐center retrospective study included 973 LDLT recipients from 2001 to 2024. Of these, 577 who underwent concomitant Spx were analyzed. SFSS grading followed the 2023 International Liver Transplantation Society consensus criteria. Prognostic factors associated with SFSS grade B/C, which required perioperative portal vein inflow control, were identified. Results: SFSS grade B/C occurred in 105 patients (18.2%) and was associated with significantly worse prognosis than grade 0/A (1‐year survival: 93.9% vs. 81.9%, p < 0.0001). The grade B/C group had higher levels of Model for End‐stage Liver Disease (MELD) score (median 18 vs. 15, p < 0.0001), neutrophil‐to‐lymphocyte ratio (NLR) (3.9 vs. 2.7, p < 0.0001), donor age (37 vs. 40 years, p = 0.0370), and donor body mass index (BMI) (22.7 vs. 21.8 kg/m 2 , p = 0.0093). Multivariate logistic regression identified NLR of ≥ 4.5, MELD score of ≥ 30, and donor age of ≥ 50 years, as independent predictors. Conclusions: SFSS grade B/C still occurred in nearly one in five patients who underwent Spx for SFSS risk mitigation during LDLT. Patients with a high recipient NLR, MELD score, or donor age are at increased risk of SFSS despite Spx. Future strategies should emphasize careful donor selection and perioperative portal inflow modulation for high‐risk cases.
- 28 January 2026
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (4) , 1165-1173
Open AccessRisk Factors for Small‐for‐Size Syndrome Grade B/C After Simultaneous Splenectomy in Adult Living‐Donor Liver Transplantation
Background: Small‐for‐size syndrome (SFSS) after adult living‐donor liver transplantation (LDLT) is a poor prognostic condition. Splenectomy (Spx) has recently been reported to help prevent SFSS and improve outcomes. This study aimed to identify risk factors for SFSS that occur despite Spx at the time of LDLT. Methods: This single‐center retrospective study included 973 LDLT recipients from 2001 to 2024. Of these, 577 who underwent concomitant Spx were analyzed. SFSS grading followed the 2023 International Liver Transplantation Society consensus criteria. Prognostic factors associated with SFSS grade B/C, which required perioperative portal vein inflow control, were identified. Results: SFSS grade B/C occurred in 105 patients (18.2%) and was associated with significantly worse prognosis than grade 0/A (1‐year survival: 93.9% vs. 81.9%, p < 0.0001). The grade B/C group had higher levels of Model for End‐stage Liver Disease (MELD) score (median 18 vs. 15, p < 0.0001), neutrophil‐to‐lymphocyte ratio (NLR) (3.9 vs. 2.7, p < 0.0001), donor age (37 vs. 40 years, p = 0.0370), and donor body mass index (BMI) (22.7 vs. 21.8 kg/m 2 , p = 0.0093). Multivariate logistic regression identified NLR of ≥ 4.5, MELD score of ≥ 30, and donor age of ≥ 50 years, as independent predictors. Conclusions: SFSS grade B/C still occurred in nearly one in five patients who underwent Spx for SFSS risk mitigation during LDLT. Patients with a high recipient NLR, MELD score, or donor age are at increased risk of SFSS despite Spx. Future strategies should emphasize careful donor selection and perioperative portal inflow modulation for high‐risk cases.
- Open Access
- 26 December 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (3) , 861-870
Comparison of Anatomical and Non‐Anatomical Resection in Low Microvascular Invasion Risk Solitary Hepatocellular Carcinoma ≤ 5 cm
Background: The role of anatomical resection (AR) in hepatocellular carcinoma (HCC) remains controversial, particularly for tumors ≤ 5 cm without vascular invasion. We aimed to evaluate the long‐term outcomes of AR versus non‐anatomical resection (NAR) in solitary HCC presumed negative for microvascular invasion (MVI) and intrahepatic metastasis (IM). Methods: We retrospectively analyzed 303 patients with solitary HCC who underwent hepatectomy between 2002 and 2019. Predictive factors for MVI and IM were identified, and 214 patients with solitary HCC ≤ 5 cm and predicted absence of MVI and IM were further analyzed. We compared the perioperative and oncological outcomes between the AR ( n = 94) and NAR ( n = 120) groups. Subsequently, we conducted propensity score matching ( n = 41 per group) and performed subgroup analyses based on tumor size. Results: Des‐γ‐carboxy prothrombin > 150 mAU/mL was identified as an independent predictor for MVI and IM. Compared with the NAR group, the AR group had a significantly longer operative time, greater blood loss, and higher rate of complications, but showed no significant differences in recurrence‐free survival and overall survival. Recurrence‐free survival and overall survival remained comparable between the two groups after propensity score matching. Subgroup analyses by tumor size (0–2.0 and 2.1–5.0 cm) showed no prognostic advantage for AR over NAR. Conclusions: For solitary HCC ≤ 5 cm without predicted MVI and IM, NAR and AR result in comparable long‐term outcomes. The resection strategy should prioritize remnant liver function over anatomical extent.
- 26 December 2025
- Published by Wiley in Annals of Gastroenterological Surgery
- Vol. 10 (3) , 861-870
Open AccessComparison of Anatomical and Non‐Anatomical Resection in Low Microvascular Invasion Risk Solitary Hepatocellular Carcinoma ≤ 5 cm
Background: The role of anatomical resection (AR) in hepatocellular carcinoma (HCC) remains controversial, particularly for tumors ≤ 5 cm without vascular invasion. We aimed to evaluate the long‐term outcomes of AR versus non‐anatomical resection (NAR) in solitary HCC presumed negative for microvascular invasion (MVI) and intrahepatic metastasis (IM). Methods: We retrospectively analyzed 303 patients with solitary HCC who underwent hepatectomy between 2002 and 2019. Predictive factors for MVI and IM were identified, and 214 patients with solitary HCC ≤ 5 cm and predicted absence of MVI and IM were further analyzed. We compared the perioperative and oncological outcomes between the AR ( n = 94) and NAR ( n = 120) groups. Subsequently, we conducted propensity score matching ( n = 41 per group) and performed subgroup analyses based on tumor size. Results: Des‐γ‐carboxy prothrombin > 150 mAU/mL was identified as an independent predictor for MVI and IM. Compared with the NAR group, the AR group had a significantly longer operative time, greater blood loss, and higher rate of complications, but showed no significant differences in recurrence‐free survival and overall survival. Recurrence‐free survival and overall survival remained comparable between the two groups after propensity score matching. Subgroup analyses by tumor size (0–2.0 and 2.1–5.0 cm) showed no prognostic advantage for AR over NAR. Conclusions: For solitary HCC ≤ 5 cm without predicted MVI and IM, NAR and AR result in comparable long‐term outcomes. The resection strategy should prioritize remnant liver function over anatomical extent.
- Open Access
- 27 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 29 (3) , 88-92
Feasibility of non-routine abdominal drainage for minimally invasive liver surgery: study protocol for a multicenter randomized controlled clinical trial
Introduction: Minimally invasive liver surgery (MILS), such as laparoscopic and robotic hepatectomy, has been developed and is an effective alternative to traditional open hepatectomy. Although surgical techniques and postoperative management have improved, many institutions continue to perform routine postoperative abdominal drainage. In open hepatectomy, abdominal drainage after uncomplicated hepatectomy increases overall and wound-related complications without a reduction in the risk of intra-abdominal fluid collections that require intervention. The aim of this study was to elucidate the feasibility of non-routine abdominal drainage for patients who undergo MILS for tumors located outside the posterosuperior area. Methods and analysis: This study is a multicenter randomized controlled trial and will recruit 182 patients who undergo MILS. The study duration is three years, including a 2-year registration duration. Participants will be randomly assigned to either the non-routine drainage group or the routine drainage group (ratio 1:1) to prove non-inferiority. The primary study outcome is the incidence of in-hospital postoperative complications of Clavien–Dindo grade ≥ II. The secondary study outcomes are length of postoperative hospital stay, incidences of specific postoperative complications and all postoperative complications, and surgery-related mortality. Ethics and dissemination: Ethical approval has been obtained from the institutional review board (No. 20232008). The results of this study will be published in international peer-reviewed journals.
- 27 May 2025
- Published by Wolters Kluwer Health in International Journal of Surgery Protocols
- Vol. 29 (3) , 88-92
Open AccessFeasibility of non-routine abdominal drainage for minimally invasive liver surgery: study protocol for a multicenter randomized controlled clinical trial
Introduction: Minimally invasive liver surgery (MILS), such as laparoscopic and robotic hepatectomy, has been developed and is an effective alternative to traditional open hepatectomy. Although surgical techniques and postoperative management have improved, many institutions continue to perform routine postoperative abdominal drainage. In open hepatectomy, abdominal drainage after uncomplicated hepatectomy increases overall and wound-related complications without a reduction in the risk of intra-abdominal fluid collections that require intervention. The aim of this study was to elucidate the feasibility of non-routine abdominal drainage for patients who undergo MILS for tumors located outside the posterosuperior area. Methods and analysis: This study is a multicenter randomized controlled trial and will recruit 182 patients who undergo MILS. The study duration is three years, including a 2-year registration duration. Participants will be randomly assigned to either the non-routine drainage group or the routine drainage group (ratio 1:1) to prove non-inferiority. The primary study outcome is the incidence of in-hospital postoperative complications of Clavien–Dindo grade ≥ II. The secondary study outcomes are length of postoperative hospital stay, incidences of specific postoperative complications and all postoperative complications, and surgery-related mortality. Ethics and dissemination: Ethical approval has been obtained from the institutional review board (No. 20232008). The results of this study will be published in international peer-reviewed journals.